Behçet’s disease (BD), a chronic systemic vasculitis, has distinct geographical and ethnic variation. Data regarding the epidemiology of patients with BD in the U.S. are limited; therefore, we sought to describe BD patient characteristics and medication use in the U.S., and compared them with data from patients from endemic regions. We conducted a cross-sectional study using data from the RISE registry (2014–2018). Patients aged ≥ 18 years with BD were included. Sociodemographic and treatment information was extracted. We compared patients from the RISE registry to data from other published studies of patients with BD from endemic areas. One thousand three hundred twenty-three subjects with BD from the RISE registry were included. Mean age was 48.7 ± 16.3 years, female to male ratio was 3.8:1, and 66.7% were White. The most frequently used medications included glucocorticoids (67.6%) and colchicine (55.0%). Infliximab and adalimumab were the most used biologics (14.5% and 14.1%, respectively); 3.2% of patients used apremilast. The RISE registry had more women (79.3%), and patients were older compared to previously published BD studies from endemic areas. Methotrexate and TNFi were more commonly reported in RISE (21.8% and 29.4%) compared to studies from Egypt and Turkey. Colchicine, cyclosporine, and cyclophosphamide were more commonly used in cohorts from Egypt, Turkey, and Iran. Findings from the largest BD dataset in the U.S. suggest that BD patients are predominantly female. Further research is needed to explore the reasons for the higher prevalence of BD among women in the U.S. and its possible impact on disease severity and management.

中文翻译：

---

美国白塞氏病的流行病学和治疗：风湿病信息学有效性系统 (RISE) 注册中心的见解以及与流行地区其他已发表的队列的比较

白塞氏病 (BD) 是一种慢性系统性血管炎，具有明显的地理和种族差异。有关美国双相情感障碍患者流行病学的数据有限；因此，我们试图描述美国双相情感障碍患者的特征和药物使用情况，并将其与来自流行地区患者的数据进行比较。我们使用 RISE 注册中心（2014-2018 年）的数据进行了一项横断面研究。年龄 ≥ 18 岁的 BD 患者被纳入。提取了社会人口统计和治疗信息。我们将 RISE 登记处的患者与其他已发表的针对流行地区 BD 患者的研究数据进行了比较。来自 RISE 登记处的 1,323 名 BD 受试者被纳入其中。平均年龄为 48.7 ± 16.3 岁，男女比例为 3.8:1，66.7% 为白人。最常用的药物包括糖皮质激素（67.6%）和秋水仙碱（55.0%）。英夫利昔单抗和阿达木单抗是最常用的生物制剂（分别为 14.5% 和 14.1%）；3.2%的患者使用阿普斯特。与之前发表的来自流行地区的 BD 研究相比，RISE 登记处的女性较多 (79.3%)，且患者年龄较大。与埃及和土耳其的研究相比，RISE 中报告的甲氨蝶呤和 TNFi 更为常见（21.8% 和 29.4%）。秋水仙碱、环孢素和环磷酰胺在埃及、土耳其和伊朗的队列中更常用。美国最大的双相情感障碍数据集的研究结果表明，双相情感障碍患者主要是女性。需要进一步研究来探讨美国女性双相情感障碍患病率较高的原因及其对疾病严重程度和治疗的可能影响。